Itacitinib clinical trials
Also written INCB039110.
How each study uses itacitinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the itacitinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
45 studies that test it; most in 2020 (8)
| Year | Studies |
|---|---|
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 7 |
| 2019 | 7 |
| 2020 | 8 |
| 2021 | 4 |
| 2022 | 3 |
| 2023 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 23 · Other 22
Incyte Corporation (22) · M.D. Anderson Cancer Center (4) · University of Pennsylvania (2) · Assistance Publique - Hôpitaux de Paris (2) · Washington University School of Medicine (2) · City of Hope Medical Center (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Fondazione per la Medicina Personalizzata (1)
Often tested with
Tested in the same studies.
Parsaclisib (2) · Cyclophosphamide (1) · Tacrolimus (1) · Tepotinib (1) · Dezapelisib (1) · Chimeric Antigen Receptor T-Cell Therapy|Chimeric Antigen Receptor T-cell Therapy (1) · Chimeric Antigen Receptor T-cells (1) · Adrenal Cortex Hormones (1)
Related medicines
As reviewed, each with the page that says it.
- One of JAK inhibitors source
- One of Protein Kinase Inhibitors source
- One of Tyrosine kinase inhibitors (TKIs) source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test itacitinib.
- Nov 2026Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)Phase 2 · Incyte Corporation
- Feb 2027Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell TherapyPhase 2 · H. Lee Moffitt Cancer Center and Research Institute
- Mar 2027Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell TransplantsPhase 2 · City of Hope Medical Center
- Apr 2027Itacitinib for the Prevention of Graft Versus Host DiseasePhase 2 · M.D. Anderson Cancer Center
Studies
Open first, then newest update. How each study uses itacitinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 45
- Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell TherapyRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT05757219Written as Itacitinib
- Safety and Efficacy of Itacitinib in Adults With Systemic SclerosisRecruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT04789850Written as Itacitinib
- Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell TransplantsActive, not recruitingPhase 2City of Hope Medical CenterNCT05364762Written as Itacitinib
- Itacitinib for the Prevention of Graft Versus Host DiseaseActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT04859946Written as Itacitinib
- Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older PatientsActive, not recruitingPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT05823571Written as Itacitinib
- A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of ItacitinibTerminatedPhase 2Incyte CorporationNCT04640025Written as itacitinib
- Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)Active, not recruitingPhase 2Incyte CorporationNCT04509700Written as parsaclisib + itacitinib
- Itacitinib + Everolimus in Hodgkin LymphomaActive, not recruitingPhase 1/2University of PennsylvaniaNCT03697408Written as Itacitinib
- Study of INCB040093 in Subjects With Previously Treated B-Cell MalignanciesCompletedPhase 1Incyte CorporationNCT01905813Written as INCB040093 + itacitinib
- Itacitinib in Advanced Hepatocellular CarcinomaCompletedPhase 1Imperial College LondonNCT04358185Written as Itacitinib
- Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint InhibitorsWithdrawnPhase 2Douglas JohnsonNCT05660421Written as Itacitinib
- Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung CancerTerminatedPhase 2Incyte CorporationNCT02257619Written as Itacitinib
- An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung CancerCompletedPhase 1/2Incyte CorporationNCT02917993Written as Itacitinib
- Treatment of Non Severe Hemophagocytosis Lymphohistiocytosis With ITACITINIBCompletedPhase 2Assistance Publique - Hôpitaux de ParisNCT05063110Written as Itacitinib
- Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell TransplantTerminatedPhase 1M.D. Anderson Cancer CenterNCT04239989Written as Itacitinib
- Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric SubjectsTerminatedPhase 1/2Incyte CorporationNCT03721965Written as Itacitinib
- GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host DiseaseTerminatedPhase 1Incyte CorporationNCT03320642Written as Itacitinib
- GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseaseTerminatedPhase 2/3Incyte CorporationNCT03584516Written as Itacitinib
- Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung TransplantationTerminatedPhase 1/2Incyte CorporationNCT03978637Written as Itacitinib
- GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host DiseaseCompletedPhase 3Incyte CorporationNCT03139604Written as Itacitinib
See all 45 studies that test itacitinib →
Given beside what is tested · 6 — itacitinib is usual care or a partner of the new treatment
- Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)RecruitingPhase 1/2Michael SavonaNCT04061421Written as Itacitinib
- A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell TherapyCompletedPhase 2Incyte CorporationNCT04071366Written as Itacitinib
- A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)CompletedPhase 1/2Incyte CorporationNCT02018861Written as Itacitinib
- An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced MalignanciesTerminatedPhase 1/2Incyte CorporationNCT02265510Written as INCB039110
- Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid TumorsTerminatedPhase 1Incyte CorporationNCT02559492Written as Itacitinib
- INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin LymphomaTerminatedPhase 2Incyte CorporationNCT02456675Written as itacitinib
Codes
What other systems call itacitinib · ClinicalTrials.gg INT001651
- MeSH (NLM) C000718170itacitinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 19J3781LPMITACITINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27891174itacitinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C116855ItacitinibOne source FDA
- DrugBank DB12154One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718170 | itacitinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 19J3781LPM | ITACITINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27891174 | itacitinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C116855 | Itacitinib | One source FDA |
| DrugBank | DB12154 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.